CN111629752B - 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物 - Google Patents

用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物 Download PDF

Info

Publication number
CN111629752B
CN111629752B CN201880074372.5A CN201880074372A CN111629752B CN 111629752 B CN111629752 B CN 111629752B CN 201880074372 A CN201880074372 A CN 201880074372A CN 111629752 B CN111629752 B CN 111629752B
Authority
CN
China
Prior art keywords
ser
seq
gly
leu
determining region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880074372.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111629752A (zh
Inventor
权南勋
李真英
金圣勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Semeti Co ltd
Original Assignee
Semeti Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semeti Co ltd filed Critical Semeti Co ltd
Publication of CN111629752A publication Critical patent/CN111629752A/zh
Application granted granted Critical
Publication of CN111629752B publication Critical patent/CN111629752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
CN201880074372.5A 2017-09-15 2018-09-17 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物 Active CN111629752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0118917 2017-09-15
KR20170118917 2017-09-15
PCT/KR2018/010903 WO2019054819A1 (ko) 2017-09-15 2018-09-17 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
CN111629752A CN111629752A (zh) 2020-09-04
CN111629752B true CN111629752B (zh) 2024-03-29

Family

ID=65723723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880074372.5A Active CN111629752B (zh) 2017-09-15 2018-09-17 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物

Country Status (10)

Country Link
US (1) US11965038B2 (https=)
EP (1) EP3682898A4 (https=)
JP (1) JP7511241B2 (https=)
KR (1) KR102163465B1 (https=)
CN (1) CN111629752B (https=)
AU (1) AU2018332491B2 (https=)
BR (1) BR112020004935A8 (https=)
CA (1) CA3084461C (https=)
RU (1) RU2749591C1 (https=)
WO (1) WO2019054819A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020166A2 (pt) 2017-03-27 2020-06-30 Medicinal Bioconvergence Research Center anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular
CA3084461C (en) 2017-09-15 2025-06-17 Zymedi Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION
WO2020060156A1 (ko) * 2018-09-17 2020-03-26 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118694A (zh) * 2010-06-01 2013-05-22 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928136D0 (en) * 1999-11-29 2000-01-26 Rose Marlene L Organ rejection and associated conditions
KR100961392B1 (ko) 2008-04-15 2010-06-07 이화여자대학교 산학협력단 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
RU2465330C1 (ru) * 2008-08-18 2012-10-27 Сеул Нэшнл Юниверсити Индастри Фаундейшн СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК
AU2008360729A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
KR101009501B1 (ko) * 2008-10-10 2011-01-18 서울대학교산학협력단 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물
US9127268B2 (en) * 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
US11111396B2 (en) 2014-10-17 2021-09-07 C3 Nano, Inc. Transparent films with control of light hue using nanoscale colorants
US10050713B2 (en) 2015-03-02 2018-08-14 Futurewei Technologies, Inc. Optical transceiver using duplex media, self-homodyne detection (SHD), coherent detection, and uncooled laser
KR20180069146A (ko) 2016-12-14 2018-06-25 만도헬라일렉트로닉스(주) 주차 조향 보조 시스템 및 그 제어방법
BR112019020166A2 (pt) 2017-03-27 2020-06-30 Medicinal Bioconvergence Research Center anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular
CA3084461C (en) * 2017-09-15 2025-06-17 Zymedi Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118694A (zh) * 2010-06-01 2013-05-22 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction;DAE GYU KIM等;《Nature Chemical Biology》;第10卷(第10期);第29-34页 *

Also Published As

Publication number Publication date
BR112020004935A8 (pt) 2022-07-05
AU2018332491B2 (en) 2022-04-14
KR102163465B1 (ko) 2020-10-07
CA3084461A1 (en) 2019-03-21
CA3084461C (en) 2025-06-17
US20210070880A1 (en) 2021-03-11
EP3682898A4 (en) 2021-09-29
BR112020004935A2 (pt) 2022-04-19
CN111629752A (zh) 2020-09-04
RU2749591C1 (ru) 2021-06-15
EP3682898A1 (en) 2020-07-22
WO2019054819A1 (ko) 2019-03-21
KR20190031189A (ko) 2019-03-25
AU2018332491A1 (en) 2020-04-30
US11965038B2 (en) 2024-04-23
JP2020534273A (ja) 2020-11-26
JP7511241B2 (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
KR101589135B1 (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
CN111629752B (zh) 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物
EP4692116A1 (en) Single-domain antibody of gdf15 and use thereof
CN110603055B (zh) 与暴露于细胞膜上的赖氨酰-tRNA合成酶N末端区域特异性结合的抗体
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
KR102114191B1 (ko) 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
WO2018182284A1 (ko) 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
US12006357B2 (en) Transthyretin antibodies and uses thereof
RU2781304C1 (ru) Антитело для специфического связывания с n-концевым доменом лизил-трнк-синтетазы, экспонированным на внеклеточной мембране
JP7453694B2 (ja) 細胞外膜に露出されるリシル－ｔＲＮＡ合成酵素のＮ－末端領域に特異的に結合する抗体
US12421307B2 (en) Anti-FGF19 antibodies
CN120137037A (zh) Cd3的特异性结合蛋白及其制备方法和应用
JP2023169439A (ja) 抗ヒトｔｒｐｖ２抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210113

Address after: Han Guojingjidao

Applicant after: Biotechnology Co.,Ltd.

Address before: Han Guojingjidao

Applicant before: Medical Life Fusion Research Group

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211101

Address after: Inchon, Korea

Applicant after: Semeti Co.,Ltd.

Address before: Gyeonggi Do, South Korea

Applicant before: Biotechnology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant